Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogeneity, and samples from at least two regions are nec...

Full description

Saved in:
Bibliographic Details
Main Authors: Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis
Format: article
Language:EN
Published: Nature Portfolio 2019
Subjects:
Science
Q
Online Access:https://doaj.org/article/3b5c30a996d54c2086cfff5a285a1014
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogeneity, and samples from at least two regions are necessary to detect treatment-induced clonal shifts

Similar Items